A Phase I, Open-Label, Dose Escalation Study of Daily Dosing With BB-10901.

Trial Profile

A Phase I, Open-Label, Dose Escalation Study of Daily Dosing With BB-10901.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Lorvotuzumab mertansine (Primary)
  • Indications Carcinoid tumour; Neuroendocrine carcinoma; Non-small cell lung cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Biomarker
  • Sponsors ImmunoGen
  • Most Recent Events

    • 09 Mar 2016 Results published in the Investigational New Drugs
    • 25 Mar 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov reocrd.
    • 25 Mar 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov reocrd.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top